At a glance
ClinicalIndex Comparison RecordN/ACompleted· 296 enrolled
Drug / intervention
MACFIMS +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif on Employment Status, Quality of Life and Cognition: a Pilot Study
Centre hospitalier de l'Université de Montréal (CHUM)·interventional·Posted Mar 3, 2015·Updated May 24, 2017
In Brief
A clinical study evaluating MACFIMS and MSQoL-54 for Multiple Sclerosis. Completed, enrolled 296 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether Rebif has an impact on employment status, quality of life and cognition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCanada
CollaboratorsEMD Serono Canada Inc.
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedMar 2015
Primary CompletionMay 2015
Study CompletionDec 2016
TodayJul 2026
First PostedMar 3, 2015
Enrollment StartJan 1, 2014
Primary CompletionMay 1, 2015
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.3 years ago
Interventions
MACFIMSother
Cognitive evaluation of 50 participants
MSQoL-54other
Quality of life questionnaires